Bausch + Lomb Corporation
BLCO Healthcare Medical Instruments & Supplies
Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.
- Revenue
- +7.34%
- EPS
- +222.4%
- Free cash flow
- +182.5%
- Total debt
- +2.93%
Quarter to September 2026, against a year earlier
Follow BLCO
Alert me
Bausch + Lomb Corporation (BLCO) P/E ratio
Bausch + Lomb Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 946× (February 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 786× | 1,966.00% |
| FY2021 | 38.0× | 0.00% |
| FY2020 | 38.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 19 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RGEN Repligen Corporation compare | n/m |
| MMED MiniMed Group, Inc. compare | n/m |
| BLCO Bausch + Lomb Corporation | n/m |
| TFX Teleflex Incorporated compare | 18.2× |
| COO The Cooper Companies, Inc. compare | 21.3× |
| ALGN Align Technology, Inc. compare | 24.0× |
| AVTR Avantor, Inc. compare | 30.8× |
| MMSI Merit Medical Systems, Inc. compare | 32.5× |
| ATR AptarGroup, Inc. compare | 34.1× |
| Medical Instruments & Supplies industry median | 30.8× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on BLCO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement